Foamix Pharmaceuticals (NASDAQ:FOMX) released its quarterly earnings data on Monday. The specialty pharmaceutical company reported ($0.41) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.07), Fidelity Earnings reports. Foamix Pharmaceuticals had a negative net margin of 2,115.11% and a negative return on equity of 75.99%.
Shares of Foamix Pharmaceuticals stock traded up $0.05 during trading hours on Tuesday, reaching $3.53. 38,406 shares of the company’s stock were exchanged, compared to its average volume of 2,007,239. The company has a 50 day moving average of $3.18 and a two-hundred day moving average of $2.86. Foamix Pharmaceuticals has a fifty-two week low of $1.97 and a fifty-two week high of $4.48. The stock has a market cap of $264.76 million, a P/E ratio of -2.08 and a beta of 1.57.
FOMX has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded shares of Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 22nd. Bank of America reaffirmed a “buy” rating and issued a $11.00 target price on shares of Foamix Pharmaceuticals in a research note on Friday, August 9th. ValuEngine raised shares of Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Cowen set a $30.00 target price on shares of Foamix Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, September 23rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price (up from $10.00) on shares of Foamix Pharmaceuticals in a research note on Monday, October 21st. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $15.40.
In other news, CFO Ilan Hadar sold 9,420 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $3.50, for a total transaction of $32,970.00. Following the completion of the transaction, the chief financial officer now directly owns 123,671 shares in the company, valued at approximately $432,848.50. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 2.95% of the company’s stock.
About Foamix Pharmaceuticals
Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea.
Featured Article: Ex-Dividend
Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.